pro13192
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00452127)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pro13192
- pro131921
- pro131921
- pro 131921
- pro-131921
- pro131921 monoclonal antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00496132 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2007 | Genentech |
| NCT00452127 | Phase 1/Phase 2 (Phase 2) | May 1, 2007 | Genentech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 2 | 2 | 1 | 2007 |
1 organizations
Page 1 / 1